The trial will include patients with non-small cell lung, breast, ovarian, gastric, esophageal, and colorectal cancers.
With this approval, patients who receive the anti-amyloid drug biweekly for 18 months can then consider switching to a monthly dosing regimen.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback